Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 8/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ICMT | O60725 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23436562 | 0.86 | HDAC1 (0.40) | HDAC1CSNK2A1HPGDKAT2AKAT2B | |
| SCHEMBL12640254 | 0.82 | HDAC1 (0.46) | HDAC1CSNK2A1ICMT | |
| SCHEMBL29307652 | 0.78 | DDX3X (0.37) | HDAC1CSNK2A1 | |
| SCHEMBL21424859 | 0.78 | HDAC1 (0.35) | HDAC1CSNK2A1HPGDFOLH1MAPT | |
| SCHEMBL25892151 | 0.77 | ZDHHC20 (0.42) | HDAC1CSNK2A1FOLH1 | |
| SCHEMBL17490608 | 0.77 | EPHX2 (0.46) | HDAC1CSNK2A1 | |
| SCHEMBL17776274 | 0.77 | EPHX2 (0.46) | HDAC1CSNK2A1FOLH1 | |
| SCHEMBL25892142 | 0.76 | ANPEP (0.38) | HDAC1CSNK2A1HPGDKAT2AKAT2B | |
| SCHEMBL26066670 | 0.76 | HDAC1 (0.40) | HDAC1CSNK2A1FOLH1 | |
| SCHEMBL13437065 | 0.76 | FOLH1 (0.46) | HDAC1CSNK2A1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | HDAC1 2335/4885CSNK2A1 1413/4885HPGD 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.